Walid Abi-Saab sold $17k of QURE
Chief Medical Officer at uniQure N.V.. 1,660 shares at an average of $9.95, traded Mar 2, 2026, filed Mar 4, 2026.
Score components
- +15RoleOfficer
- 0Trade size$17k at market
- 0Share of holdings soldSold 1.1% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000904454-26-000148, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 2, 2026 | SOpen-market sale Ordinary Shares | -1,660 | $9.95 | $17k | 148,777 | Mar 4, 2026 |
Related signals
Other insiders at uniQure N.V. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | QUREsell uniQure N.V. | Walid Abi-Saab Chief Medical Officer | $7,320 808 shares | -0% | |
| 21Weak | uniQure N.V. | Robert Gut director | $857k 31,434 shares | -44% | |
| 33Weak | uniQure N.V. | Jack Kaye director | $1.2M 38,810 shares | -128% | |
| 19Weak | uniQure N.V. | Christian Klemt Chief Financial Officer | $945k 18,000 shares | -8% | |
| 33Weak | uniQure N.V. | Matthew C Kapusta CEO, Managing Director | $9.4M 226,316 shares | -26% | |
| 30Weak | uniQure N.V. | Walid Abi-Saab Chief Medical Officer | $20k 1,466 shares | -1% | |
| 35Weak | uniQure N.V. | Madhavan Balachandran director | $31k 2,112 shares | -5% | |
| 37Weak | uniQure N.V. | Robert Gut director | $48k 3,336 shares | -6% | |
| 35Weak | uniQure N.V. | Rachelle Suzanne Jacques director | $31k 2,112 shares | -7% | |
| 35Weak | uniQure N.V. | Jack Kaye director | $31k 2,112 shares | -9% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.